Shanghai ImmuneOnco Raises $6.4 Million for Immunotherapies

Shanghai's ImmuneOnco Biopharma raised $6.4 million in a Pre-B round to support its pre-clinical portfolio of immunotherapy cancer candidates. Founded in 2015, the company is developing bi-specific antibodies, novel recombinant proteins, target-specific natural killer (NK) cells, a target-activated NK (TANK™) cell therapy, a CAR-T cell therapy, and mAbs that target immune regulation pathways. Tian Wenzhi, chairman and general manager, said the capital would support clinical studies of two ImmuneOnco candidates, IMM01 and IMM0306. More details.... Share this with colleagues: // //